Caplin Point Laboratories (BOM:524742) Total Liabilities : ₹3,506 Mil (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Caplin Point Laboratories Total Liabilities?

Caplin Point Laboratories's Total Liabilities for the quarter that ended in Mar. 2024 was ₹3,506 Mil.

Caplin Point Laboratories's quarterly Total Liabilities declined from Sep. 2023 (₹3,103.70 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹3,505.60 Mil).

Caplin Point Laboratories's annual Total Liabilities increased from Mar. 2022 (₹2,264.40 Mil) to Mar. 2023 (₹2,841.30 Mil) and increased from Mar. 2023 (₹2,841.30 Mil) to Mar. 2024 (₹3,505.60 Mil).

Caplin Point Laboratories Total Liabilities Historical Data

The historical data trend for Caplin Point Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caplin Point Laboratories Total Liabilities Chart

Caplin Point Laboratories Annual Data

Trend

Jun15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

1,691.86

1,602.40

2,264.40

2,841.30

3,505.60

Caplin Point Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2,841.30	-	3,103.70	-	3,505.60

Caplin Point Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Caplin Point Laboratories's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3305.6	+	(9.2	+	190.8
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3,506

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	26973.8	-	23468.2
	=	3,506

Caplin Point Laboratories's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3305.6	+	(9.2	+	190.8
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3,506

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	26973.8	-	23468.2
	=	3,506

Caplin Point Laboratories Total Liabilities Related Terms

Thank you for viewing the detailed overview of Caplin Point Laboratories's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Caplin Point Laboratories (BOM:524742) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Caplin Point Laboratories Ltd (BOM:524742) » Definitions » Total Liabilities

Traded in Other Exchanges

CAPLIPOINT:India

Address

Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096

Website

https://www.caplinpoint.net

Caplin Point Laboratories Ltd is the India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, liquid orals, dry powder, soft gels, penems injections, suppositories. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops. The business of the company is organized into the following product segments, Antibiotics, Nsaids, Ophthalmics, Pain Management, and Antiulcers. Its products have a presence in the Latin American and African markets.

Caplin Point Laboratories (BOM:524742) Headlines

No Headlines